Medlab Clinical

Medlab Clinical EV/EBIT

Delisted

The EV/EBIT (Enterprise Value to EBIT) of Medlab Clinical (MDC.AX) as of Oct 19, 2026 is -6.68. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.09 — a change of 220.25% (lower).

EV/EBIT

-6.68

YoY

220.25%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Medlab Clinical is 2024 -6.68 . EV/EBIT (Enterprise Value to EBIT) of Medlab Clinical was 2023 -2.09 . It decreases by 220.25% lower compared to the previous year.

The Medlab Clinical EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-1.80 AUD
Jan 1, 2020
-1.10 AUD
Jan 1, 2021
-1.38 AUD
Jan 1, 2022
-1.80 AUD
Jan 1, 2023
-2.09 AUD
Jan 1, 2024
-6.68 AUD
Jan 1, 2025 (e)
-2.53 AUD
Jan 1, 2026 (e)
-1.06 AUD
The Medlab Clinical EV/EBIT history
YEAREV/EBITYoY
est-1.06-58.10%
est-2.53-62.13%
-6.68+220.25%
-2.09+15.84%
-1.80+30.59%
-1.38+25.68%
-1.10-38.95%
-1.80-43.91%
-3.20-18.74%
-3.94-2.86%
-4.06+4.99%
-3.87-53.82%
-8.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medlab Clinical Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Medlab Clinical's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Medlab Clinical's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Medlab Clinical's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Medlab Clinical grows earnings faster than its peers.

Medlab Clinical Stock analysis

What does Medlab Clinical do? Medlab Clinical Ltd is an innovative biotechnology company focused on the development and commercialization of medical products and services. The company was founded in Australia in 2012 and is now based in Sydney. Since its founding, Medlab has established itself as a leading provider of diagnostic and therapeutic products. Medlab's business model consists of three different divisions. The first division is pharmaceutical development, where Medlab works on the development of new medications for the treatment of conditions such as fibromyalgia, pain, or ADHD. Medlab is particularly innovative in the development of medications based on the use of cannabinoids that are approved for medical use. The second division of Medlab is the research and development of nutritional supplements. The company works on the development of innovative products to improve general well-being and support health. An example is the nutritional supplement NRGBiotic, which contains special probiotic bacteria that help regulate the intestinal flora and thereby strengthen the immune system. The third division of Medlab is clinical diagnostics. The company offers various medical diagnostic tests, such as the test for food intolerances. This test is based on a blood sample and allows for targeted dietary changes in individuals with intolerance. Medlab aims to improve people's lives by developing and providing innovative products and services for medical care. Medlab's products are designed to promote the health and well-being of patients and customers and improve their quality of life. One outstanding product from Medlab is NanoCBD, an innovative form of cannabinoid delivery for medical purposes. The advantage of NanoCBD is that it has increased bioavailability due to the nanoparticles, resulting in faster and more effective action than conventional CBD products. Another product from Medlab is the pain medication NanaBis, which works faster and more effectively than other pain medications due to its unique formulation. Thanks to its special composition, NanaBis can also be taken by patients with severe chronic pain who do not respond to other pain medications. Medlab has established itself as a global company and is present worldwide. The company maintains partnerships and collaborations with renowned research institutions and doctors in Europe, North America, Australia, and Asia. Medlab works closely with medical professionals to ensure that the company's products and services meet the highest quality standards and meet the needs of patients and customers. Overall, Medlab Clinical Ltd has established itself as an innovative and reliable company in the medical industry. With its clear focus on the development of innovative medications, nutritional supplements, and diagnostic systems, Medlab significantly contributes to improving the healthcare system and increasing the well-being of people worldwide. Medlab Clinical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medlab Clinical stock

EV/EBIT (Enterprise Value to EBIT) of Medlab Clinical is -6.68 in 2024.

EV/EBIT (Enterprise Value to EBIT) of Medlab Clinical changed from -2.09 to -6.68, representing a 220.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Medlab Clinical since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Medlab Clinical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medlab Clinical

All Key Metrics — Medlab Clinical